<DOC>
	<DOCNO>NCT02897050</DOCNO>
	<brief_summary>This multi-center , open-label , phase II randomize control trial evaluate efficacy docetaxel ( T ) combine metronomic cyclophosphamide/capecitabine ( mCX ) follow fluorouracil /epirubicin/cyclophosphamide ( FEC ) versus T follow FEC neoadjuvant chemotherapy treat woman triple negative breast cancer ( TNBC ) , study anti-tumor immune effect metronomic neoadjuvant chemotherapy . 186 stage M0 TNBC patient primary tumor &gt; 2cm image axillary lymph node &gt; 2cm image randomly enrol receive neoadjuvant T combine mCX ( 3 cycle ) follow FEC ( 3 cycle ) T ( 3cycles ) follow FEC ( 3 cycle ) surgery . The primary end point pathological complete response ( pCR ) rate , secondary end point include : clinical response rate , toxicity , breast-conserving rate , Ki67 CD31 reduction rate , change percentages peripheral blood tumor microenvironmental regulatory T cell ( Treg ) , T helper cell ( Th ) , CD8+ T cell , tumor-specific CTL , change tumor microenvironmental immune cytokine . Once significant statistical difference term pCR rate two group , 3-year disease-free survival ( DFS ) 3-year overall survival ( OS ) include secondary end point . The aim study determine whether neoadjuvant T combine metronomic CX follow FEC significantly increase pCR rate TNBC acceptable toxicity , explore anti-tumor immune effect metronomic neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Trial Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed FEC Women With Operable Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>The patient sign write informed consent The patient present nonmetastatic unilateral invasive ERnegative ( IHC &lt; 10 % ) , PRnegative ( IHC &lt; 10 % ) , HER2negative breast cancer primary breast tumor &gt; 2cm image axillary lymph node &gt; 2cm imaging . 18 year old &lt; age &lt; 70 year old . The patient history hormone therapy , chemotherapy , breast cancer surgery radiotherapy . The patient normal cardiac function echocardiography . The patient ' ECOG score ≤2 . The patient swallow pill . The result patient ' blood test follow : Hb≥90g/L ; WBC≥4E+9/L ; Plt≥100E+9/L ; Neutrophils≥1.5E+9/L ; ALT AST ≤ triple normal upper limit ; TBIL ≤ 1.5 time normal upper limit ; Creatinine ≤ 1.5 time normal upper limit . The patient cancer time history cancer except controlled skin basal cell carcinoma skin squamous cell carcinoma carcinoma situ cervix uterus ; The patient active infection suitable chemotherapy ; The patient severe noncancerous disease . The patient bilateral breast cancer male breast cancer inflammatory breast cancer . The patient undergoing current administration anticancer therapy , attend clinical trial . The patient special condition understand write informed consent , demented hawkish . The patient allergic history contraindication interventional drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>